Table 1.
Descriptive statistics of the study cohort at baseline.
| Total cohort (N = 850) | Restricted cohorta (n = 215) | |
|---|---|---|
| Age at MS diagnosis, mean (SD), years | 30.5 (8.7) | 31.3 (9.0) |
| Age at MS onsetb, mean (SD), years | 28.5 (8.4) | 29.0 (8.4) |
| Disease durationc, mean (SD), years | 5.4 (5.6) | 5.0 (6.1) |
| Sex, n (%) | ||
| Male | 232 (27%) | 57 (26.5%) |
| Female | 618 (73%) | 158 (73.5%) |
| MS phenotype, n (%) | ||
| RRMS | 768 (90%) | 187 (87%) |
| PPMS | 7 (1%) | 2 (1%) |
| SPMS | 27 (3%) | 11 (5%) |
| Unspecified | 42 (5%) | 15 (7%) |
| Missing | 6 (1%) | 0 (0%) |
| EDSSd, median (Q1, Q3) | 3.0 (2.0, 4.5) | 2.5 (2.0, 4.4) |
| Number of previous DMTs, n (%) | ||
| 0 | 204 (24%) | 83 (39%) |
| 1 | 239 (28%) | 47 (22%) |
| ≥ 2 | 407 (48%) | 85 (40%) |
| JCV status, n (%) | ||
| Negative | 138 (16%) | 104 (48%) |
| Positive | 41 (5%) | 21 (10%) |
| Missing | 671 (79%) | 90 (42%) |
DMT: disease-modifying therapy; EDSS: Expanded Disability Status Scale; JCV: John Cunningham virus; MS: multiple sclerosis; PPMS: primary progressive multiple sclerosis; RRMS: relapsing-remitting multiple sclerosis; SD: standard deviation; SPMS: secondary progressive multiple sclerosis.
The restricted study cohort included MS patients from the Finnish MS Register who had additional data from a Finnish university hospital and whose first natalizumab infusion was between 1/2014 and 12/2018.
127 patients in the total study cohort and 14 patients of restricted study cohort did not have information on the age at MS onset available.
The time from MS diagnosis to the initiation of natalizumab treatment.
484 patients in the total study cohort and 129 patients of restricted study cohort did not have EDSS information available.